Evidence map›Paper›PMID 39624248›Full record

ArticleJTO clinical and research reports2024

Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced

Jacqueline V Aredo, Heather A Wakelee, Kavitha J Ramchandran, Joel W Neal, Maximilian Diehn, Angela Bik-Yu Hui, Ameen Salahudeen, Bernice Kwong, Gerald J Berry, H Henry Guo and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Jacqueline V AredoDivision of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
Heather A WakeleeDivision of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
Kavitha J RamchandranDivision of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
Joel W NealDivision of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
Maximilian DiehnDepartment of Radiation Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
Angela Bik-Yu HuiDepartment of Radiation Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
Ameen SalahudeenDepartment of Internal Medicine, University of Illinois Cancer Center, Chicago, Illinois.
Bernice KwongDepartment of Dermatology, Stanford University School of Medicine, Stanford, California.
Gerald J BerryDepartment of Pathology, Stanford University School of Medicine, Stanford, California.
H Henry GuoDepartment of Radiology, Stanford University School of Medicine, Stanford, California.
Kristen CunananQuantitative Sciences Unit, Stanford University School of Medicine, Stanford, California.
Shireen ValiCellworks Group, South San Francisco, California (Prior).
Danny PancirerDivision of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
Vivian TsangDivision of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
Grace HwangDivision of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
Monica LozaDivision of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
Brittany JohnsonDivision of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
Isabelle BlanchardDivision of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
Sukhmani K PaddaDivision of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: There are no standard targeted treatment options for advanced Methods: This single-arm phase II study included regorafenib 80 to 120 mg oral daily and oral methotrexate dose escalated to tolerability from 10 to 20 mg twice weekly during the first cycle. Both agents were administered on weeks 1 to 3 of each 4-week cycle. The primary end point was progression-free survival. Results: In total, 18 patients with Conclusions: Combination treatment of regorafenib and oral methotrexate in patients with

Indexed as

ctDNAKRAS mutationMethotrexateRegorafenibTargeted therapy

Identifiers

PMID39624248
PMCPMC11609302

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.